Nutriband (NASDAQ:NTRB - Get Free Report) issued its earnings results on Monday. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.06), Zacks reports. The firm had revenue of $0.64 million during the quarter, compared to analysts' expectations of $0.71 million. Nutriband had a negative return on equity of 54.49% and a negative net margin of 338.51%.
Nutriband Price Performance
NTRB stock traded up $0.07 on Friday, reaching $6.37. 47,142 shares of the company's stock were exchanged, compared to its average volume of 78,483. The firm has a market cap of $70.75 million, a PE ratio of -8.97 and a beta of 1.19. The company has a quick ratio of 4.83, a current ratio of 4.96 and a debt-to-equity ratio of 0.01. The stock has a fifty day moving average of $5.97 and a 200-day moving average of $5.70. Nutriband has a twelve month low of $3.35 and a twelve month high of $11.78.
Analyst Upgrades and Downgrades
Separately, Noble Financial initiated coverage on shares of Nutriband in a report on Wednesday, January 22nd. They issued an "outperform" rating and a $13.00 price objective for the company.
Read Our Latest Analysis on Nutriband
About Nutriband
(
Get Free Report)
Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.
Further Reading
Before you consider Nutriband, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nutriband wasn't on the list.
While Nutriband currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
